[Quality standard] Company Standard (YBS01402011)
[Suitable population] This product is suitable for susceptible population aged 16 and above. It is recommended for individuals exposed to high risk of hepatitis E virus infection, such as those engaged in animal husbandry and catering, students, officers and soldiers, women of childbearing age, travelers to endemic areas and so on.
[Route of Administration] 3 doses of intramuscular injection following the 0, 1 months, 6 months schedule, that is the first dose on the first day, the second dose one month after the first injection，and the third dose six months after the first injection.
[Shelf life] 2-8℃ for 36 months
•Launched in Oct. 2012, China
•The world's first vaccine against hepatitis E
•Up to 4.5 years, the long-term efficacy against clinical HE was 93.3% (78.6-97.9) and 86.8% (71.0-94.0) in per-protocol and intention-to-treat analysis, respectively.
•Complete phase I, II, III, IV Clinical Trial conducted in China